Prothena (PRTA) Competitors $6.59 -0.23 (-3.40%) Closing price 03:59 PM EasternExtended Trading$6.56 -0.03 (-0.49%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. IDYA, EWTX, IMCR, TVTX, MESO, GPCR, JANX, EVO, SPRY, and ADPTShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include IDEAYA Biosciences (IDYA), Edgewise Therapeutics (EWTX), Immunocore (IMCR), Travere Therapeutics (TVTX), Mesoblast (MESO), Structure Therapeutics (GPCR), Janux Therapeutics (JANX), Evotec (EVO), ARS Pharmaceuticals (SPRY), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Prothena vs. IDEAYA Biosciences Edgewise Therapeutics Immunocore Travere Therapeutics Mesoblast Structure Therapeutics Janux Therapeutics Evotec ARS Pharmaceuticals Adaptive Biotechnologies IDEAYA Biosciences (NASDAQ:IDYA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Do insiders and institutionals have more ownership in IDYA or PRTA? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 2.5% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 9.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, IDYA or PRTA? IDEAYA Biosciences has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Does the MarketBeat Community believe in IDYA or PRTA? Prothena received 473 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. However, 71.86% of users gave IDEAYA Biosciences an outperform vote while only 70.56% of users gave Prothena an outperform vote. CompanyUnderperformOutperformIDEAYA BiosciencesOutperform Votes14371.86% Underperform Votes5628.14% ProthenaOutperform Votes61670.56% Underperform Votes25729.44% Does the media prefer IDYA or PRTA? In the previous week, IDEAYA Biosciences had 2 more articles in the media than Prothena. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 7 mentions for Prothena. IDEAYA Biosciences' average media sentiment score of 1.27 beat Prothena's score of 1.27 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IDYA or PRTA? IDEAYA Biosciences currently has a consensus price target of $54.27, indicating a potential upside of 182.16%. Prothena has a consensus price target of $51.71, indicating a potential upside of 656.06%. Given Prothena's higher possible upside, analysts clearly believe Prothena is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.93Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has stronger earnings & valuation, IDYA or PRTA? Prothena has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M240.66-$274.48M-$3.59-5.36Prothena$137.94M2.67-$147.03M-$2.08-3.29 Is IDYA or PRTA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Prothena's net margin of -90.50%. Prothena's return on equity of -22.67% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -26.74% -25.54% Prothena -90.50%-22.67%-19.68% SummaryIDEAYA Biosciences and Prothena tied by winning 9 of the 18 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$359.62M$6.47B$5.32B$8.43BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-2.909.0626.7719.71Price / Sales2.61254.27390.22118.35Price / CashN/A65.8538.2534.62Price / Book0.646.416.754.50Net Income-$147.03M$143.98M$3.23B$248.32M7 Day Performance-0.52%1.97%1.55%-0.09%1 Month Performance-29.93%4.09%12.22%12.89%1 Year Performance-69.04%-2.83%16.71%7.33% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.8602 of 5 stars$6.59-3.4%$51.71+685.0%-68.5%$354.61M$137.94M-2.86130IDYAIDEAYA Biosciences3.6695 of 5 stars$18.08+1.5%$54.27+200.2%-53.3%$1.58B$7M-5.4880Positive NewsAnalyst ForecastEWTXEdgewise Therapeutics2.9076 of 5 stars$14.79+0.1%$40.22+172.0%-18.4%$1.56BN/A-9.8660Positive NewsIMCRImmunocore2.7673 of 5 stars$31.00+2.1%$58.13+87.5%-37.9%$1.55B$333.58M-32.63320Positive NewsTVTXTravere Therapeutics2.9882 of 5 stars$17.01+1.3%$31.79+86.9%+151.1%$1.51B$273.53M-4.15460Positive NewsMESOMesoblast1.8339 of 5 stars$11.55-1.5%$18.00+55.8%+42.4%$1.48B$5.67M0.0080Gap DownGPCRStructure Therapeutics1.9634 of 5 stars$25.00-0.7%$78.00+212.0%-32.6%$1.43BN/A-33.78136Gap UpJANXJanux Therapeutics2.737 of 5 stars$24.17-0.5%$95.25+294.1%-45.5%$1.43B$9.34M-20.6630Positive NewsEVOEvotec1.4989 of 5 stars$3.97-2.2%$5.93+49.5%-21.2%$1.41B$788.22M0.004,200Positive NewsGap DownSPRYARS Pharmaceuticals2.4108 of 5 stars$14.26+4.9%$31.00+117.4%+61.0%$1.40B$89.15M-27.9690News CoveragePositive NewsAnalyst DowngradeAnalyst RevisionADPTAdaptive Biotechnologies4.1131 of 5 stars$9.20+1.7%$9.83+6.9%+160.5%$1.40B$189.53M-8.44790Positive News Related Companies and Tools Related Companies IDEAYA Biosciences Competitors Edgewise Therapeutics Competitors Immunocore Competitors Travere Therapeutics Competitors Mesoblast Competitors Structure Therapeutics Competitors Janux Therapeutics Competitors Evotec Competitors ARS Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRTA Stock Free PRTA Stock Alerts